Is the $1–20/life saved by a pneumococcus vaccine still available? At what scale?

I would imagine that the marginal cost increases as patients more facile to reach are addressed. Still, the 2016 Disease Control Priorities (DCP3) report cites this figure (Figure 17.2, page 323).

It may be worth asking clinics or governments in emerging economies, especially in least developed countries, where it is possible that many communities do not receive basic healthcare.

Then, this investment can be highly competitive with top rated global health interventions such as malaria prevention ($600–$3,500/equivalent of life saved) (30–3,500× more cost-effective).